Diabetes Mellitus, Type 2 MedDRA version: 17.0 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861
Conditions
Sponsors
Novo Nordisk A/S
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Type 2 diabetes mellitus 2. Male or female =18 years of age 3. HbA1c 7.0 - 10.0% [53 mmol/mol - 86 mmol/mol] (both inclusive), confirmed by the central laboratory 4. Stable daily treatment with metformin (=1500 mg or max tolerated dose) ± pioglitazone (=30 mg) for at least 90 days prior to screening 5. Body Mass Index (BMI) =40 kg/m^2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 278 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 138
Exclusion criteria
Exclusion criteria: 1. Current use of any anti-diabetic drugs (except for metformin and pioglitazone) or anticipated change in concomitant medication, which, in the opinion of the investigator, could interfere with the glucose metabolism (e.g. systemic corticosteroids) 2. Previous and / or current treatment with insulin (short term treatment due to intercurrent illness, including gestational diabetes, is allowed at the discretion of the investigator) 3. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists, sulpfonylurea, glinides, dipeptidyl peptidase 4 (DPP-4) inhibitors or sodium-glucose co-transporter 2 (SGLT2) inhibitors within 90 days prior to the screening visit 4. Impaired liver function, defined as alanine aminotransferase (ALAT) =2.5 times upper normal range (UNR) 5. Impaired renal function defined as serum-creatinine =133 µmol/L ( =1.5 mg/dL) for males and =125 µmol/L ( =1.4 mg/dL) for females, or as defined according to local contraindications for metformin 6. Screening calcitonin =50 ng/L 7. Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment, according to investigator's clinical judgment 8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 9. History of pancreatitis (acute or chronic)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To confirm the efficacy of insulin degludec/liraglutide (IDegLira), using a once weekly titration algorithm, in controlling glycaemia in insulin-naïve subjects with type 2 diabetes mellitus (T2DM), inadequately controlled on metformin alone or in combination with pioglitazone. This is done by comparing the difference in change from baseline HbA1c (glycosylated haemoglobin) after 32 weeks of treatment to a non-inferiority limit of 0.30 % for once weekly titration vs. twice weekly titration.;Secondary Objective: To compare efficacy in terms of other measures of glycaemic control and safety of IDegLira titrated using a once weekly vs. twice weekly algorithm after 32 weeks of treatment.;Primary end point(s): Change from baseline in HbA1c ;Timepoint(s) of evaluation of this end point: After 32 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Responder (Yes/No) for: – HbA1c <7.0% – HbA1c =6.5%;Timepoint(s) of evaluation of this end point: After 32 weeks of treatment | — |
Countries
Austria, Bulgaria, Canada, Czech Republic, European Union, Hungary, Russian Federation, Serbia, Slovakia, United States
Contacts
Public ContactGlobal Clinical Registry (GCR,1452)
Novo Nordisk A/S
Outcome results
None listed